APA

Mazurov A. V., Pevzner D. V., Semenov A. V., Antonova O. A., Dudnik O. A., Khaspekova S. G., Vlasik T. N., Samko A. N., Staroverov I. I. & Ruda M. I. (20031106). [Pharmacodynamics, safety, and clinical effects of a novel glycoprotein IIb/IIIa antagonist framon during high risk coronary angioplasty]. : Kardiologiia.

Chicago

Mazurov A V, Pevzner D V, Semenov A V, Antonova O A, Dudnik O A, Khaspekova S G, Vlasik T N, Samko A N, Staroverov I I and Ruda M Ia. 20031106. [Pharmacodynamics, safety, and clinical effects of a novel glycoprotein IIb/IIIa antagonist framon during high risk coronary angioplasty]. : Kardiologiia.

Harvard

Mazurov A. V., Pevzner D. V., Semenov A. V., Antonova O. A., Dudnik O. A., Khaspekova S. G., Vlasik T. N., Samko A. N., Staroverov I. I. and Ruda M. I. (20031106). [Pharmacodynamics, safety, and clinical effects of a novel glycoprotein IIb/IIIa antagonist framon during high risk coronary angioplasty]. : Kardiologiia.

MLA

Mazurov A V, Pevzner D V, Semenov A V, Antonova O A, Dudnik O A, Khaspekova S G, Vlasik T N, Samko A N, Staroverov I I and Ruda M Ia. [Pharmacodynamics, safety, and clinical effects of a novel glycoprotein IIb/IIIa antagonist framon during high risk coronary angioplasty]. : Kardiologiia. 20031106.